Jump to Navigation
Home ›

Dementia

Article

Medications for Treating Alzheimer’s Dementia

The Diagnosis and Treatment of Dementia

While drug companies have been working hard to come up with new options for the treatment of dementia, there have been no new FDA approvals since memantine (Namenda) hit the scene in 2003.

Normal Forgetfulness vs. Pre-Dementia: How to Distinguish Them

A 70-year old man comes into your office and asks: “Doctor, I keep misplacing my keys-am I getting Alzheimer’s?” You detect the note of anxiety in his voice, and you want to give an answer, and soon.

Here is a reasonable approach, based on the latest research data.

Medications for Dementia: An Update

It has now been a full ten years since the first of the second-generation cholinesterase inhibitors (CIs), Aricept (donepezil) was approved for Alzheimer’s dementia.

Research Update

Off-Label Use of Antipsychotics Effective for Some Indications

Over the past decade or so, atypical antipsychotic use has exploded, for both FDA approved indications and off-label treatments. A recent meta-analysis examined the efficacy (when compared to placebo), comparative effectiveness (when compared to another medication), and safety of atypicals.

SNRIs Likely No Better than SSRIs for Depression

Due to their inhibition of both serotonin and norepinephrine reuptake, the SNRIs venlafaxine (Effexor) and duloxetine (Cymbalta) have been billed as possessing an advantage over SSRIs.

Expert QA

Agitation and Depression in Older Patients

Medication Fact Sheet

Razadyne Fact Sheet

Namenda Fact Sheet

Click here to view mobile site

Current Issue

Practice Tips

May, 2013
Vol: 11 Issue: 5
Read More
Previous Issues

Topics

ADHD
Antidepressants
Antipsychotics
Anxiety Disorder
Autism Spectrum Disorder
Benzodiazepines
Bipolar Disorder
Brain Devices
Child Psychiatry
Cognitive Behavioral Therapy
Computers in Psychiatric Practice
Cultural Competence
Dementia
Depressive Disorder
Diagnostic Testing
DSM
Eating Disorders
End of Life Care
Free Articles
Gender & Sexuality
Genetics and Psychiatry
Health Care Policy
HIPAA
Hypnotics
Laboratory Testing in Psychiatry
Learning & Developmental Disabilities
Medical Comorbidities
Mood Stabilizers
Natural Medications
Neuroscience in Psychiatry
Novel Anticonvulsants
OCD
Personality Disorders
Pharmaceutical Industry
Practice Tools and Tips
Psychopharmacology Tips
Psychotherapy
PTSD
Research Updates
Risk Management
Seasonal Affective Disorder
Sexual Dysfunction
Sleep Disorders
Smoking Cessation Agents
Substance Abuse
Understanding Psychiatric Research
Weight Loss Medications
Women's Issues in Psychiatry
Printer-friendly version
Medication Fact Sheets

Search

Follow Us

The Carlat Report Twitter Feed
Carlat Report RSS
The Carlat Report Blog
The Carlat Report Fan Page

Earn CME Credit Instantly!

Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?

Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.

Click here to purchase A la Carte CME credits

Already an A la Carte subscriber? Click here to go to your a la carte page

Steve Balt Interviewed by NPR

Steve Balt on NPROur own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.

Listen to the broadcast here.

Editor-in-Chief

After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...

The 2012 Carlat Atypical Antipsychotics Table is Now Available!

With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.

See the Atypical Antipsychotics table!

TCPR Continuing Education
Accredited/Approved/Accepted by:

  • ACCME
  • AMA
  • APA
  • ABPN
  • ANCC
  • AAPA